NCT04808115撤回1 期
A Phase I Trial of Incorporating Natural Killer (K-NK) Cells for Patients With Chronic Myeloid Leukemia (CML) and Molecular Residual Disease After Tyrosine Kinase Inhibitor (TKI) Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 撤回
- 入组人数
- 12
- 主要终点
- Molecular Response
研究概览
简要总结
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with persistent or recurrent molecular residual disease (MRD) after at least one year of TKI therapy will allow patients to achieve RT-PCR negativity (MRD negative). This may have implications for future TKI cessation studies.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with non-blast phase CML by standard definition. This should be confirmed by presence of the Philadelphia chromosome or variants of the (9;22) translocation by cytogenetics, FISH or with a positive RT-PCR for BCR-ABL. Repeat marrow not required for enrollment although documentation of current chronic phase disease is required.
- •Chronic Phase CML is defined as follows:
- •<15% blasts in peripheral blood and marrow
- •<30% blasts plus promyelocytes in peripheral blood and marrow
- •<20% basophils in peripheral blood
- •>100 x 109/L platelets
- •No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly.
- •Accelerated Phase CML is defined as follows:
- •<30% blasts in blood, marrow or both
- •No evidence of extramedullary leukemic involvement with the exception of hepatosplenomegaly.
- •> 18 years of age and able to provide informed consent
- •Patients must have been on TKI therapy for CML for at least 1 year prior to enrollment at minimum goal doses.
- •Imatinib 300mg PO daily Dasatinib 70mg PO daily Nilotinib 200mg PO BID Bosutinib 300mg PO daily Ponatinib 30mg PO daily Lower than goal doses are allowed IF documented by the treating physician that the goal dose was not tolerable due to toxicity.
- •Patient must have been on their most recent TKI consistently for at least 6 months prior to enrollment on study
- •Must be expected to remain on current TKI for at least 6 months following last infusion, unless there is progression of disease.
- •Detectable BCR-ABL transcripts measured by RT-PCR at a CLIA-approved laboratory and reported on the IS with a value of >0.01% within 28 days prior to study enrollment. The chosen RT-PCR test must be sensitive enough to detect a 4.5 log reduction in BCR/ABL transcripts measured in peripheral blood.
- •Performance status must be ECOG PS 0, 1, or
- •Woman of childbearing potential and is willing to use 2 highly effective methods of contraception while receiving study treatment and for an additional 3 months after the last dose of protocol-specified therapy. Male who has a female partner of childbearing potential, and is willing to use 2 highly effective forms of contraception for at least an additional 3 months after the last dose of protocol-specified therapy.
排除标准
- •Patients who meet any of the following criteria will be excluded from the study:
- •Current blast crisis phase disease by standard definition from the NCCN
- •Pregnant or lactating females
- •On other investigational agents for CML within 4 weeks of study enrollment
- •Platelets of <50,000/mm3, ANC <500/mm3 or hemoglobin < 7.5 g.dL
- •Abnormal screening laboratory values as defined below:
- •AST (SGOT) and/or ALT (SGPT) and/or alkaline phosphatase ≥ 5 x upper limit of normal (ULN)
- •Total bilirubin >1.5 x ULN (unless related to Gilbert´s or Meulengracht disease or leukemic infiltration)
- •Creatinine ≥ 3 ULN or creatinine clearance < 50 mL/min (calculated)
- •Those with residual toxicity of >grade 1 from prior therapy in areas that may be expected to worsen over time; those with residual toxicities of grade 2 which are stable prior to enrollment and the natural history of which would be expected to be 'no change' over time are allowed; those with grade 3 or 4 residual toxicities are not.
- •Positive test for human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS)
- •Positive hepatitis B virus (HBV) or hepatitis C virus (HCV) indicating acute or chronic infection (those with prior infection that is now post treatment and PCR negative are allowed)
- •Current use of immunosuppressive medications at the time of study enrollment and within 2 weeks of any study treatments, except:
- •Intranasal, inhaled, topical steroids, or local steroid injection
- •Systemic corticosteroids at physiologic doses ≤10 mg/day of prednisone or equivalent
- •Steroids as premedication for hypersensitivity reactions at physiologic doses ≤10 mg/day of prednisone or equivalent
- •Patients with other major medical or psychiatric illnesses, which the treating physician feels, could seriously compromise tolerance or compliance to this protocol.
- •Diagnosis of prior immunodeficiency or organ transplant requiring immunosuppressive therapy
- •Any of the following in the previous 6 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, deep vein thrombosis, or symptomatic pulmonary embolism
- •Known prior or suspected hypersensitivity to study drugs or any component in their formulations
- •Active autoimmune disease that might deteriorate when receiving an immunostimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible
- •Diagnosis of any other malignancy within 3 years, except for adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms
- •Active infection requiring systemic therapy
研究组 & 干预措施
KDS-1001
Experimental
KDS-1001 is infused on Day 1 of each 14 day cycle. Patients will receive 6 cycles of KDS-1001 treatment.
干预措施: KDS-1001 (Drug)
结局指标
主要结局
Molecular Response
时间窗: End of Treatment up to two weeks
At least one (1) log reduction in IS OR negative to at least MR4.5 via PCR-based testing
Safety of KDS-1001
时间窗: End of Study up to two years
Number of adverse events as measured by self report
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple MyelomaMultiple MyelomaNCT02481934Joaquín Martínez López, MD, PhD5
暂停
1 期
Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on CancerHepatocellular CancerSquamous Cell Lung CancerBreast CancerProstate CancerPancreatic CancerColon CancerGliomaNCT00909558Envita Medical Center, Inc.24
已完成
1 期
Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy SubjectsHepatic ImpairmentNCT03369002CymaBay Therapeutics, Inc.32
已完成
1 期
Haploidentical NK Cells After Pemetrexed in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNCT03366064Asan Medical Center5
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)Non-Small-Cell Lung CancerNCT02835690Merck Sharp & Dohme LLC44